Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

Imatinib mesylate is effective in the treatment of hematologic malignancies that are
characterized by either abl-or PDGFR β-activating mutations. The drug is also active in a …

Fluorescence in situ hybridization (FISH) was used to detect 6q–, 11q–,+ 12, 13q–, 17p–and
translocations involving 14q32 in interphase nuclei from blood and/or bone marrow from …

Purpose: Validation of fluorescence in situ hybridization assays is required before using
them in clinical practice. Yet, there are few published examples that describe the validation …

Fifty years have elapsed since the discovery of the number of human chromosomes in 1956.
Newer techniques have been developed since then, ranging from the initial conventional …

Breakpoint cluster region-Abelson (BCR-ABL1) translocation is the characteristic sign of
chronic myeloid leukemia (CML). The quantitation of BCR-ABL1 messenger RNA is …

Chronic myeloid leukemia (CML) is a disease of hematopoietic stem cells and is caused by
the balanced translocations among the long arms of chromosomes 9 and 22, which are …

Translocations involving IGH are common in some lymphoid malignancies but are believed
to be rare in chronic lymphocytic leukaemia (CLL). To study the clinical utility of fluorescence …

Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic leukemia (B-
CLL) patients for (1) disease progression,(2) angiogenesis genes,(3) T-cell leukemia 1 gene …

Dual-color, dual-fusion fluorescence in situ hybridization (D-FISH) can accurately detect and
quantify cells with BCR/ABL fusion in< 1% of 500 nuclei in 80% of patients with chronic …